32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
|
|
|
- まいえ ながおか
- 7 years ago
- Views:
Transcription
1 Bisphosphonate related osteonecrosis of jaw; BRONJ BRONJ BP α-streptococcus 0 BRONJ BRONJ BP I Paget Bisphosphonate related osteonecrosis of jaw; BRONJ 2002 Marx RE, Stern DS Oral and Maxillofacial pathology 2,3 BRONJ 4,5 BRONJ BP
2 32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ BP BP
3 BRONJ α-streptcoccus Neisseria species
4 BP BP 4 15 IV BP BRONJ BRONJ 13 BRONJ 14 BP BRONJ 15 BRONJ BRONJ BRONJ 19 4
5 BRONJ 35 5 A 10 mg 0.5 mg B 1.8 mg mg 2 mg
6 α-streptcoccus Neisseria species 15 Bacteroides 2 Prebotella 2
7 BRONJ g S 600 mg 100 mg 2 g MS 100 mg Meiji Seika 200 mg 500 mg 250 mg 1 g 500 mg 9...
8 38 16 QOL 5 BP BP P-C-P R1 17 BP BP BRONJ BRONJ BRONJ 19 BRONJ BRONJ BP BP BP 20 RANKL receptor activator of nuclear factor-kb ligand BP Actinomyces, Veillonella, Eikenella, Moraxella, Fusobacterium, Bacillus, Staphylococcus, Streptococcus, and Selenomonas 24,25
9 BRONJ BRONJ BP BRONJ BP 1 Coleman RE: Future directions in the treatment and prevention of bone metastates. Am J Clin Oncol 25: S32 S38, Wang, J., Gooder, N.M.: Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: , Marx, R.E.: Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws. J oral Maxillofac Surg 61: , : , : 28 32, Bianchi ML, Limonta C, et al. Comment on: bisphosphonates and osteonecrosis of the jaw. J Rheumatol 47: 383, Boonyapakorn T, Schirmer I, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44: , Mavrokokki T, Cheng A, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65: , Murad OM, Arora S, et al. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr pract 13: , Christodoulou C, Pervena A, et al. Combination of the jaw more frequently than bisphosphonates alone. Oncology 76: , Sedghizadeh PP, Stanley K, et al. Oral bisphosphonates use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140: 61 66, : , Yoneda T, et al. Bisphosphonate-Related Osteonecrosis of the Jaw: Position Paper from the Allied Task Force. Committee of Japanese Society for Bone and Mineral Research, Osteoporosis Society Japan, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons, J Bone Miner Metab (in press) 15 Urade M, et al. Nationwide Survey for Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. J Oral Maxillofac Surg 69: e364 e371 (2011) Bartl R, Frisch B , Philipp S, Moritz B, et al. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw result of a clinical case series with an average follow-up of 20 months. Clin Oral Invest DOI /s American Dental Association Council on Scientific Affairss: Dental management of patients receiv-
10 40 ing oral bisphosphonate therapy Expert panel recommendations. JADA 137: , World of Bisphosphonate; illustrated mechanism of action and clinical use Henry DH, et al.: J Clin Oncol. 2011; 29(9): Stopeck AT, et al.: J Clin Oncol. 2010; 28(35): Fizazi K, et al.: Lancet. 2011; 377(9768): Bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. Am Fam Physician Jun 15; 85(12): Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol Mar-Apr; 52(2): Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg Jul; 49(5): Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw. Int J Immunopathol Pharmacol Apr-Jun; 23(2): Page
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004
The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
orororor oror CINAHL breast cancerhormonal therapyorendocrine therapyortamoxifenorgoserelinside effectorsymptomexperien
72017 3 資料 内分泌療法を受けている乳がん患者の苦痛体験に関する文献検討 A Literature Review regarding Distress Experienced by Breast Cancer Patients Undergoing Endocrine Therapy 四方文子 1), 鈴木久美 2) Ayako Shikata 1),Kumi Suzuki 2) キーワード
SLActive_cs4.indd
SIMPLY BETTER STRAUMANN SLActive SLActive 1 SLActive SLA SLActive SLA 2,3,4,5,6,7 SLActive 1,3,4,5,6,7,8,9 3 4 2 8 SLActive SLA SLActive SLA 1 2 3 4 5 6 7 8 1,2 SLActive 2 2 4 1 SLActive SLA SLActive 11
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
Autumn EU 22 CD P RR 9 7 EU EU 2003 OECD 8 EU OECD OECD EC Included in Society 2003 EC OECD EU
138 Vol. 44 No. 2 はじめに 20 2008 5 2007 9 EU I 障害者政策の国際比較研究 1981 80 90 1990 ADA 1 1999 OAS 2 1996 CD P RR 3 EC 2003 2004 2010 1993 10 ESCAP 4 10 2003 BMF 5 BMF 2007 9 2001 2006 12 2008 5 2000 EU EC EU Autumn
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira
26 1 : 35 45 2017 1 2 2 2 2 2 2 2 2 1 1 2 Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hirayama 1, Yoko Nakajo 2, Akemi Saito 2, Rie Hatakeyama
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
language anxiety :, language-skill-specific anxiety Cheng, Horwitz, & Schallert, Horwitz et al. Foreign Language Classroom Anxiety ScaleFLCAS Young, ;
Second Language Anxiety of JSL Learners in In and Outside the Classroom MOCHIZUKI Michiko This article discusses second language anxiety with special reference to Japanese education in in-classroom and
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎２症例
11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO
MV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
bc0710_010_015.indd
Case Study.01 Case Study.02 30 Case Study.05 Case Study.03 Case Study.04 Case Study.06 Case Study.07 Case Study.08 Case Study.21 Case Study.22 Case Study.24 Case Study.23 Case Study.25 Case Study.26
2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11
1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu
’lŁ¶Ÿ_‰ƒ52†\3(‡æ‡±)/2.’¼Œ{†E‘¼Œ{
6 I 1995 PTSD Posttraumatic Stress Disorder 2002 3 JSTSS II ABCC Atomic Bomb Casualty Commission RERF 1 1949 50 2 3 3 3 2 1 1951 ; 1958 7.3 1961 30 3 Encephalose Somatose 1961 ; 1963 132 28 1996 a 1959
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.3, No.3 July 2014 Original Article Clinical significance of classification of mixed-pattern tumor by breast ultrasound...
08_中嶋真美.indd
56 2015 pp. 175 190 CBT CBT CBT UNWTO 2015 2013 10 2015 11 3,300 2010 2030 3.3 2030 182014 1 2,450 GDP 9 2016 1 30 175 56 UNESCO 2010 Living Heritage Cultural Landscape Community-Based Tourism 2002UNWTO
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
第５８巻６号／投稿規定・目次・表２・奥付・背
Feature articles 1Why is it that allergic diseases have been increasing? Feature articles 2Space medicine and medicine for the future Review γ ε γ γ γγ α αβ et al et al et al et al et al et al Is nutritional
分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
NL09
Information September, 2005 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.9 September, 2005 3 2005 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery
Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery, Osaka Kosei-Nenkin Hospital K. Izawa and S. Wakitani
Understanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
untitled
f c Human Capital: A Theoretical and Empirical Analysis, with Special Reference to Education The Scientific Analysis of Personality Emotional Intelligence: Why It Can Matter More than IQ Psychological
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5